CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 19 enrolled
Drug / intervention
Cervical transcutaneous vagus nerve stimulation (active comparator) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05226130
NCT05226130Phase 1Completed

Non-invasive Vagal Nerve Stimulation to Improve Functional Outcomes in Veterans With Alcohol Use Disorder

VA Office of Research and Development·interventional·Posted Feb 7, 2022·Updated Jul 3, 2025

In Brief

A Phase 1 clinical trial evaluating Cervical transcutaneous vagus nerve stimulation (active comparator) and Cervical transcutaneous vagus nerve stimulation (sham comparator) for Alcohol Use Disorder. Completed, enrolled 19 participants across 1 site.

Detailed Summary

Alcohol use disorder (AUD) is a major health concern amongst Veterans as it causes poor health, lost days at work, impaired psychosocial functioning, and decreased quality of life. Current treatment options for AUD show limited effectiveness, which is exemplified by high relapse rates. Chronic heavy drinking results in psychological and physical distress during abstinence, including anxiety, irritability, and general discomfort, which increases the urge to drink to relieve these symptoms. The hypothesis of this study is that noninvasive vagal nerve stimulation (nVNS) can modify the perception of such inner bodily sensations of distress, and consequently reduces the drive to drink for relief. The aim of this study is to establish feasibility and acceptability of applying nVNS as a rehabilitative treatment for AUD in Veterans. The study will also evaluate the effect of nVNS on functional outcomes, quality of life, distress, and craving, and if nVNS alters neural activation patterns in brain regions involved in the perception and awareness of distress and pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedFeb 7, 2022
Enrollment StartMay 2, 2022
Primary CompletionMay 1, 2024
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 4.4 years ago

Interventions

Cervical transcutaneous vagus nerve stimulation (active comparator)device

Active nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that stimulates the vagus nerve.

Cervical transcutaneous vagus nerve stimulation (sham comparator)device

Sham nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that does not stimulate the vagus nerve.